NEW YORK (GenomeWeb) — Biomarker development firm Denovo Biopharma has acquired the late-stage oncology drug enzastaurin from Eli Lilly and Company, and plans to use its genotyping platform to uncover a genomic marker or markers that can support new clinical trials advancing the drug for a genomi

NEW YORK (GenomeWeb) — As part of its quest to become a catch-all provider of tools and technologies for molecular diagnostic and especially companion diagnostic development, Qiagen has added another molecular analysis platform to its portfolio.